1105 related articles for article (PubMed ID: 26258604)
1. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
[TBL] [Abstract][Full Text] [Related]
2. Adult Ocular Myasthenia Gravis Conversion: A Single-Center Retrospective Analysis in China.
Feng X; Huan X; Yan C; Song J; Lu J; Zhou L; Wu H; Qiao K; Lu J; Xi J; Luo S; Zhao C
Eur Neurol; 2020; 83(2):182-188. PubMed ID: 32526733
[TBL] [Abstract][Full Text] [Related]
3. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients.
Gunji K; Skolnick C; Bednarczuk T; Benes S; Ackrell BA; Cochran B; Kennerdell JS; Wall JR
Clin Immunol Immunopathol; 1998 Jun; 87(3):276-81. PubMed ID: 9646837
[TBL] [Abstract][Full Text] [Related]
4. Factors Affecting Generalization of Ocular Myasthenia Gravis in Patients With Positive Acetylcholine Receptor Antibody.
Apinyawasisuk S; Chongpison Y; Thitisaksakul C; Jariyakosol S
Am J Ophthalmol; 2020 Jan; 209():10-17. PubMed ID: 31562855
[TBL] [Abstract][Full Text] [Related]
5. Factors affecting outcome in ocular myasthenia gravis.
Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
[TBL] [Abstract][Full Text] [Related]
6. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients.
Hong YH; Kwon SB; Kim BJ; Kim BJ; Kim SH; Kim JK; Park KS; Park KJ; Sung JJ; Sohn EH; Lee YB; Jeong D; Joo IS; Choi BO; Choi YC;
J Neurol Sci; 2008 Oct; 273(1-2):10-4. PubMed ID: 18602121
[TBL] [Abstract][Full Text] [Related]
8. The Usefulness of Anti-acetylcholine Receptor Binding Antibody Testing in Diagnosing Ocular Myasthenia Gravis.
Chung IY; Sheth SJ; Wells KK; Campbell TG
J Neuroophthalmol; 2021 Dec; 41(4):e627-e630. PubMed ID: 32868574
[TBL] [Abstract][Full Text] [Related]
9. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
[TBL] [Abstract][Full Text] [Related]
10. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis.
Jacob S; Viegas S; Leite MI; Webster R; Cossins J; Kennett R; Hilton-Jones D; Morgan BP; Vincent A
Arch Neurol; 2012 Aug; 69(8):994-1001. PubMed ID: 22689047
[TBL] [Abstract][Full Text] [Related]
11. Antibody profile may predict outcome in ocular myasthenia gravis.
Galassi G; Mazzoli M; Ariatti A; Kaleci S; Valzania F; Nichelli PF
Acta Neurol Belg; 2018 Sep; 118(3):435-443. PubMed ID: 29858757
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies in Japanese patients with ocular myasthenia gravis.
Nagaishi A; Narita T; Woodhall M; Jacobson L; Waters P; Irani SR; Vincent A; Matsuo H
Muscle Nerve; 2021 Feb; 63(2):262-267. PubMed ID: 33094484
[TBL] [Abstract][Full Text] [Related]
13. Significance of Acetylcholine Receptor Antibody Titers in Acetylcholine Receptor Antibody-Positive Ocular Myasthenia Gravis: Generalization and Presence of Thyroid Autoimmune Antibodies and Thymoma.
Supawongwattana M; Vanikieti K; Jindahra P; Padungkiatsagul T
Clin Ophthalmol; 2023; 17():649-656. PubMed ID: 36875532
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of Ocular Myasthenia Gravis in an Argentinian Population.
Aguirre F; Villa AM
Eur Neurol; 2018; 79(3-4):113-117. PubMed ID: 29428956
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis.
Shi QG; Wang ZH; Ma XW; Zhang DQ; Yang CS; Shi FD; Yang L
Neurosci Bull; 2012 Oct; 28(5):469-74. PubMed ID: 22961471
[TBL] [Abstract][Full Text] [Related]
16. Complete stable remission and autoantibody specificity in myasthenia gravis.
Baggi F; Andreetta F; Maggi L; Confalonieri P; Morandi L; Salerno F; Bernasconi P; Montomoli C; Barberis M; Mantegazza R; Antozzi C
Neurology; 2013 Jan; 80(2):188-95. PubMed ID: 23255823
[TBL] [Abstract][Full Text] [Related]
17. Some clinico-immunological aspects in patients with ocular myasthenia gravis associated with inflammatory bowel disease.
Cojocaru IM; Cojocaru M; Tănăsescu R; Burcin C; Atanasiu AN; Mitu AC; Iliescu I; Dumitrescu L
Rom J Intern Med; 2008; 46(2):165-8. PubMed ID: 19284089
[TBL] [Abstract][Full Text] [Related]
18. Clinical manifestations of acetylcholine receptor antibody positive and negative myasthenia gravis.
Pasutharnchat N; Wacharapluesadee S; Hemachudha T
J Med Assoc Thai; 2012 Mar; 95(3):313-9. PubMed ID: 22550827
[TBL] [Abstract][Full Text] [Related]
19. Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis.
Aurangzeb S; Tariq M; Irshad M; Badshah M; Khan RS
J Pak Med Assoc; 2009 May; 59(5):289-92. PubMed ID: 19438131
[TBL] [Abstract][Full Text] [Related]
20. Acetylcholine receptor antibody in Thai generalized myasthenia gravis patients.
Jitpimolmard S; Taimkao S; Chotmongkol V; Sawanyawisuth K; Vincent A; Newsom-Davis J
J Med Assoc Thai; 2006 Jan; 89(1):68-71. PubMed ID: 16583584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
